ProQR Therapeutics
Nasdaq PRQR · Leiden, Netherlands
Works in ENT · Genetic & rare · Metabolic & endocrine · Neurology · Ophthalmology
ProQR Therapeutics is a clinical trial sponsor based in Leiden, Netherlands, listed as Nasdaq PRQR. It has 2 active clinical trials with 47 planned participants, across 5 therapeutic areas. Since 2021 it has completed 1 trial and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq PRQR
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about ProQR Therapeutics
ProQR Therapeutics is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 47 planned participants, in ENT, Genetic & rare, Metabolic & endocrine, Neurology and other areas. Since 2021 it has completed 1 trial and stopped 1 early.
ProQR Therapeutics is based in Leiden, Netherlands and is listed as Nasdaq PRQR. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with ProQR Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2022-05-11.
Approve Suite is not affiliated with ProQR Therapeutics.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.